Business Context and Reporting Period
This Form 8-K Current Report is filed by Tango Therapeutics, Inc. (TNGX) on August 6, 2026, regarding events occurring on July 31, 2026. The filing addresses the departure of Dr. Barbara Weber, who served as Executive Chair and a member of the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material change is the termination of Dr. Barbara Weber's employment as Executive Chair, effective August 3, 2026. Consequently, she resigned from all officer and board positions. The Company states this departure was not due to any disagreement regarding operations, practices, or policies.
Outlook, Risks, and Separation Terms
Upon separation, the Company offered Dr. Weber the following benefits contingent on executing a Separation Agreement:
- Severance: Base salary payments through December 31, 2026, paid in substantially equal installments.
- Health Benefits: Reimbursement for monthly COBRA premiums through December 31, 2026.
- Equity Acceleration: Accelerated vesting of options and restricted stock units that would have vested over the subsequent 12 months had she remained employed.
- Option Extension: Extended post-termination exercise period for vested options and accelerated awards until the earlier of August 3, 2027, or the original expiration date.
- Incentive Compensation: A pro-rata portion of the 2026 annual incentive compensation, payable no later than March 15, 2027.
The filing includes standard forward-looking statement disclaimers regarding the execution of the Separation Agreement and references risk factors detailed in the Company's 2025 Form 10-K.
Investor Verification Checklist
- Verify the execution and terms of the Separation Agreement once filed by the Company.
- Confirm the appointment of a new Executive Chair or interim leadership structure.
- Review the impact of the equity acceleration on the Company's share count and dilution.
- Monitor subsequent filings for any changes to the Board of Directors composition.